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Recent advances in Immuno-Oncology (IO) have shown
that the immune system can be activated to induce long
term durable anti-tumor responses. For IO drug devel-
opment, immune activation is typically explored using
rat surrogate antibodies in immunocompetent mouse
models. While these models can be used to show effi-
cacy in vivo, the development of anti-drug immune
responses to experimental protein-based therapeutics
can arise. Immunogenicity of surrogate antibodies may
therefore represent an important obstacle to the evalua-
tion of the anti-tumor efficacy of immune-modulator
antibodies in syngeneic models.
A recent publication has shown that the surrogate rat
IgG2b/l GITR agonistic antibody DTA-1 can induce the
development of anaphylaxis in mice upon repeated intra-
peritoneal dosing (3rd i.p. ≥ 1.0 mg/kg). Total IgE and
anti-rat variable/Fc domain anti-drug IgG1 and IgG2b
antibodies (ADAs) were detected in serum. Low levels of
DTA-1 specific anti-idiotypic ADAs were also detected.
The development of anaphylaxis was suggested to be due
to GITR as a target. An alternative hypothesis is the
potential antigenicity of the therapeutic itself. To this end,
chimerized (rat V domains/mouse constant regions) and
murinized (95% mouse sequence) DTA-1-based surrogate
antibodies with a murine IgG2c heavy chain isotype were
created. Murinized IgG2c/l DTA-1 (EC50 ~ 1.0 nM) and
chimeric IgG2c/ DTA-1 (EC50 ~ 1.3 nM) showed similar
cell surface GITR-binding affinity as the parental rat anti-
body (EC50 ~ 0.96 nM). Chimerization and murinization
of DTA-1 did not affect GITR-induced T cell proliferation
(3H-thymdine incorporation), cytokine release (IFNg, IL-
2), and viability. Murinized IgG2c/l DTA-1 (EC50 ~ 0.06
μg/ml) and chimeric IgG2c/ DTA-1 (EC50 ~ 0.05 μg/ml)
showed similar NFB signaling in vitro as the parental
rIgG2b/l DTA-1 (EC50 ~ 0.07 μg/ml). Finally, treatment
of C57BL/6J mice with the chimerized and murinized
DTA-1 antibodies on a C57BL/6J-matched IgG2c isotype
resulted in reduced development and severity of anaphy-
laxis (3 doses, i.p., 3.0 mg/kg) as measured by drop of
body temperature, behavioral effects, serum IgE and ADA
levels. These results suggest that careful murinization and
the selection of a strain-matched heavy chain isotype con-
stitute important factors for the generation of ideal surro-
gate antibodies for testing IO mechanisms in vivo.
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